
Teliso-V Plus Osimertinib Active, Tolerable in TKI-Resistant NSCLC
Telisotuzumab vedotin (Teliso-V; Emrelis) plus osimertinib (Tagrisso) showed clinical activity and was well tolerated in patients with EGFR-mutant non–small cell lung cancer (NSCLC) and c-Met overexpression who had progressed after prior osimertinib, …